Sector: Pharma
Licences of 18 pharma companies cancelled for manufacturing spurious medicines | India News
The government on Tuesday cancelled the licences of 18 pharmaceutical companies for manufacturing of spurious medicines following an inspection by the Drugs Controller General of India (DCGI) on 76 companies across 20 states. “Huge crackdown under way on pharma companies across the country related to manufacturing of spurious medicines,” news agency ANI reported quoting sources. … Read more
Sanofi drug to treat ‘smoker’s lung’ clears trial, says report
Sanofi’s asthma drug Dupixent met all targets in a trial to treat “smoker’s lung”, potentially adding billions to the French drugmaker’s growth prospects, but also underscoring a heavy reliance on its bestseller. In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic … Read more
Eris buying a part of dermatology portfolio of Glenmark
Eris Lifesciences is acquiring 9 dermatology brands from Glenmark Pharma. The brands are – Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands. The acquisition is for the India and Nepal Territories Consideration for the transaction is Rs 340 crore payable in cash. Turnover of the acquired brands: FY 20 – … Read more
Advent takes controlling stake in Suven Pharmaceuticals
Private Equity major, Advent has confirmed that it has entered into a definitive agreement to acquire a controlling stake in Suven Pharmaceuticals (SP). Advent is acquiring 50.1% from the promoters (Jasti Property and Equity Holdings Private Limited) at Rs 495/ share totalling Rs 6,313 cr. Above considration is 100% cash payable by Advent to the … Read more
Ajanta Promoters sell some stake. Continue to retain significant.
Ajanta Pharma has informed that two of it’s prom0ter entities have sold stake totalling 4.38% into the Company through open market transactions. Total Promoter stake consequently has reduced from 70.48% to 66.1% Stake has been sold by Aayush M. Agrawal, trustee Aayush Agrawal Trust (3.03%)Â and Ravi P. Agrawal, Trustee Ravi Agrawal Trust (1.35%) Reports … Read more